Published in Gene Therapy Weekly, April 22nd, 2004
Apc(min) mice, which are predisposed to intestinal polyposis, were treated with a selective synthetic agonist of peroxisome proliferator-activated receptor-delta (PPAR-delta)," wrote investigators at Vanderbilt University.
"Exposure of Apc(min) mice to the PPAR-ligand GW501516 resulted in a significant increase in the number and size of intestinal polyps. The most prominent effect was on polyp size; mice treated with the PPAR-delta activator had a fivefold increase in the number of polyps larger than 2 mm," R.A. Gupta and colleagues reported.
"Our results implicate PPAR-delta...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly